JAMA ophthalmology
-
Multicenter Study
Vismodegib for periocular and orbital basal cell carcinoma.
Basal cell carcinoma (BCC) represents 90% of malignant eyelid tumors and is locally invasive and destructive, if left untreated. ⋯ Vismodegib seems to be well-tolerated and effective for treating periocular and orbital BCC in about half of all cases. Patients receiving treatment should be monitored for new squamous cell carcinomas at uninvolved sites.